In an interview with The Center for Biosimilars, Ha Kung Wong discussed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) “patent dance” framework for biosimilar patent proceedings, which helps streamline patent disputes, potentially reducing litigation and encouraging early settlements. He also discussed ongoing legislative efforts that may impact the biosimilar sector, such as legislation that would limit the number of patents that could be asserted in a patent litigation, The Biosimilar Red Tape Elimination Act, the Patent Eligibility and Restoration Act of 2023, and increased congressional scrutiny of pharmacy benefit managers (PBMs). Wong answered questions regarding antitrust lawsuits related to biosimilars and combatting patent thickets.
The full interview with The Center for Biosimilars can be found here.
